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Background: The ability of recombinant antibodies to adequately penetrate into tumours is a key factor in achieving
therapeutic effect; however, the behaviour of antibodies at a cellular level in tumours is poorly understood. The
purpose of this study was to investigate those factors that influence the macroscopic and microscopic intratumoural
distribution of an IgG1-humanized antibody, huA33, in colorectal tumours.
Methods: Twelve patients were infused with radiolabelled huA33 at 7 days prior to elective surgery for colorectal
carcinoma. Macroscopic huA33 uptake was determined by both gamma well counter and autoradiography
measurements of the resected tumour specimens. Microscopic uptake was then quantitated at a cellular level
and compared to vascular penetrance. The impact of variation in tumour antigen (GPA33) expression, tumour
size, specimen type (primary vs metastatic), presence of macroscopic necrosis, and tumour vasculature on huA33
uptake were examined.
Results: The I-huA33 uptake in whole tumour sections was (mean ± SD) 5.13 ± 2.71 × 10−3% injected dose per gram
(ID/g). GPA33 was expressed in all viable tumour cells, and huA33 uptake was excellent regardless of tumour size and
specimen type. In tumours with macroscopically evident central necrosis (n = 5), huA33 uptake in tumour necrotic
centres was lower than in viable peripheries (0.606 ± 0.493 vs 2.98 ± 2.17 × 10−3%ID, p = 0.06). However, when
corrected for low cell viability in necrotic centres, uptake of huA33 at the cellular level was highly comparable to that
in the more viable tumour periphery (7.10 ± 5.10 × 10−9 vs 3.82 ± 3.67 × 10−9%ID/cell, p = 0.4). In the five patients
who exhibited macroscopic necrosis in their tumours, huA33 showed excellent tissue penetration, with a maximum
penetration distance of 26 μm in peripheral tumour regions and 118 μm in central regions. No correlation was
observed between 131I-huA33 uptake in tumour on a cellular basis and tumour vascularity.
Conclusions: In patients with colorectal carcinoma, monoclonal antibody huA33 effectively targets viable tumour
cells in all cellular milieus examined, including effective penetration into necrotic tumour centres, a novel and
therapeutically important finding.
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There is increasing interest in the use of humanized
monoclonal antibodies to treat epithelial cancers. This
technique is attractive owing to limited chemotherapy
options for many such cancers and the relatively low
toxicity of using tumour-specific radiolabeled monoclonal
antibodies. Many unlabeled monoclonal antibodies (mAbs)
do not demonstrate clinically significant anti-cancer activity,
despite induction of complement-dependent cytotoxicity
(CDC) and antibody-dependent cellular cytotoxicity (AD
CC). Hence, attempts have been made to utilize the tar-
geting ability of mAbs to deliver radioactive isotopes or
other cytotoxic molecules to individual cancer cells [1,2].
In order for antibody therapy approaches to be effective,
it is necessary for the antibody to adequately penetrate
within tumours after intravenous administration. Previous
studies have found variable uptake in epithelial tumours
depending on tumour size, histological type, vascularity,
degree of necrosis, antigen expression, antibody size and
affinity, antibody internalization, and other factors that
are less well understood [3-10]. Suboptimal response to
antibody therapy may be due to poor or non-uniform
penetration of antibody into certain tumour areas such
as central necrotic regions which lack an adequate
blood supply [11]. Effective intratumoural penetration
is even more important for antibody-drug conjugates
which rely on direct cellular contact to effect cell kill.
Despite this, detailed understanding of the impact of
antigen expression and vascular density on the distribution
of humanized antibodies in tumours, and penetrance into
metastatic lesions following systemic infusion, is lacking.
One of the most promising targets in colorectal cancer
is the A33 antigen (hereafter referred to as GPA33): a
transmembrane glycoprotein of the immunoglobulin super-
family with a molecular weight of 43 kDa [12-14]. GPA33
consists of two extracellular Ig domains, a single transmem-
brane domain, and a short intracellular tail containing
four acylation sites proximal to the transmembrane
domain [12,14]. Extensive immunohistochemical analysis
of malignant and normal tissues has demonstrated that
the antigen is homogeneously expressed by more than
95% of colon cancers and in the normal intestinal mucosa,
but not in other epithelial tissues [15,16]. Previous radio-
immunotherapy studies using iodinated murine A33 mAb
have shown the therapeutic potential of the GPA33
antibody system in patients with metastatic colorectal
cancer [17-19].
HuA33 is a humanized monoclonal antibody (mAb)
directed against GPA33 and has been studied in phase I
trials in patients with colorectal cancer [20-25]. Biodis-
tribution studies with 131I and 124I have shown selective
and rapid localization of huA33 to colorectal carcinoma
on imaging [20,22,23,26]. Tumour localization of huA33
was observed within 24 to 48 h post injection, increasedover 7 days, and was retained in tumour for over a month
following infusion [20,22,23]. As expected, the uptake in
the colon and small bowel was also seen, but decreased
over 7 to 10 days. Importantly, there was no evidence
of non-selective binding to normal tissues. The present
study examined tumours from one of these trials [23]
in order to explore the intratumoural microdistribution
and kinetics of huA33 in vivo, with particular focus on
the quantitative cellular uptake and vascular penetrance
of huA33 in viable and necrotic tumours.
Methods
Patient eligibility and treatment
Patient eligibility and treatment has previously been
described [23]. In brief, patients with colorectal cancer
who were also scheduled for resection of primary or
secondary tumour, or for intrahepatic artery catheter
insertion, were recruited. Patients were required to be
between 18 and 70 years old. Any chemotherapy, radio-
therapy, and immunotherapy had to be completed at
least 4 weeks prior to trial entry. Patients had to have a
Karnofsky performance status of ≥70% and acceptable
major organ function: serum creatinine <0.2 mmol/L,
serum bilirubin <20 mmol/L, granulocytes >1.5 × 109/L,
platelets > 100 × 1012/L, prothrombin time <1.3× control.
All patients gave written informed consent to partici-
pate in this study. The protocol was approved by the
Human Research Ethics Committee of the Austin Hospital,
Melbourne, Australia and the Protocol Review Committee,
Ludwig Cancer Research, New York, USA.
Eligible patients received a single intravenous infusion
of 296 to 370 MBq (8 to 10 mCi ) of 131I− and 37 to
74 MBq (1 to 2 mCi) of 125I− conjugated to huA33 (IgG1)
over a 30-min period, at antibody dose levels of 0.25, 1, 5,
and 10 mg/m2. 125I− and 131I− were used to assist with
both imaging and autoradiography studies. Seven days
later, surgery was performed and tumour samples were
obtained for histology and autoradiography. Surgery
comprised complete tumour resection (of either the
primary tumour or metastases) or biopsy of accessible
tissue for patients having surgery only for placement of
intrahepatic artery catheter.
All patients underwent gamma camera imaging on day
0 after infusion of 131I-huA33 and on at least three further
occasions up to day 7 following infusion. Single photon
emission computed tomography (SPECT) images of a
region of the body with known tumour were also
obtained on at least one occasion during this period.
All gamma camera images were acquired on a dual-
headed gamma camera (Trionix Research Laboratories,
Twinsburg, OH, USA). Whole body images were performed
as sweeps in a 1,024 × 256 bit matrix, and a standard of
known 131I activity was included in the field of view to
allow dosimetry calculations. In selected patients, resected
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determination of regional localisation of 131I-huA33.
Quantification of macroscopic 131I-huA33 tumour uptake
The magnitude of 131I-huA33 uptake in whole tumour
was assessed using gamma well counter measurements
(Packard Instruments, Melbourne, Australia) in all 12
patients. Each tumour was divided into subsections
which were weighed individually and counted in a gamma
counter (set to the 131I window) together with the appro-
priate counting standards. Results were expressed as
percent injected dose per gram (%ID/g) tissue.
The magnitude of 131I-huA33 uptake was confirmed
by whole tumour autoradiography in four patients whose
tumours were suitable for evaluation using this tech-
nique (patients 4, 5, 7, 11); two other patients (patients 1
and 2) could not be assessed due to technical problems
and six patients (patients 3, 6, 8 to 10, 12) had tumours
which were too large to allow whole tumour radiography.
For autoradiography, the resected tissue was weighed
and bisected with a portion fixed in 10% neutral buffered
formalin, embedded in paraffin, and stored at room
temperature. Tissue sections were cut at a thickness
of 5 μm and mounted onto SuperFrost® Plus slides
(Menzel-Glaser, Braunschweig, Germany). Paraffin sections
were exposed to x-ray film (Agfa Mammoray, Mortsel,
Belgium or Hyperfilm-βmax, Amersham International
plc, Aylesbury, UK) for 4 to 21 days. X-ray film was
then developed in D19 developer (Eastman Kodak Co.,
Rochester, NY, USA) and fixed in Ilford Rapidfix (Ilford
Imaging Australia, Mt. Waverley, Victoria, Australia). A set
of radioactivity standards was prepared by applying known
amounts of 125I/131I to discs of tissue sections 3 mm in
diameter and 5-μm thick mounted onto SuperFrost® Plus
slides. These standards were exposed simultaneously with
the radioactive biopsy sections to allow quantitation of anti-
gen density by computerized densitometry using an image
analysis system (VideoPro32, Leading Edge, Adelaide,
Australia). The grey value of the pixels on x-ray film
was converted to %ID/g for quantitation of antibody
uptake. High-power images of haematoxylin and eosin
(H&E) sections were captured using a microscope and
attached digital camera (Olympus, Tokyo, Japan).
Assessment of GPA33 expression
The GPA33 expression on cells was probed using murine
anti-A33 antibody (Ludwig Cancer Research, New York,
NY, USA) in fresh frozen sections. The concentrations
used were optimized for GPA33 detection (2.5, 5, and
10 μg/ml for 30 min) and bound antibody detected by
application of a biotinylated sheep-anti-mouse IgG
(1/500 dilution, Southern Biotechnology Associates
Inc. Birmingham, AL, USA) for 30 min followed by strep-
tavidin peroxidase complex (1/1,000 dilution, Silenus,Amrad Operations P/L, Melbourne, Australia). Negative
controls for both antibodies were either secondary anti-
body alone or isotype control antibodies.
Assessment of microvessel density and intercapillary
distance for CD31-positive vessels
CD31-positive blood vessels were determined by staining
for CD31 expression (Clone JC70A; Dako A/S Glostrup,
Denmark) in paraffin sections which were deparaffinized
and rehydrated by microwaving in a citrate buffer (pH 6.0)
for 10 min. Sections were then treated with 3% H2O2
for 10 min to eliminate endogenous peroxidase activity,
used 0.1% avidin and 0.01% biotin for 10 min to block
endogenous biotin and avidin activity respectively, and
treated with protein blocking agent (Immunon™, Shandon,
Pittsburgh, PA, USA) at a 1:1 dilution for 10 min to
reduce non-specific binding. JC70A was used at 3.5 μg/ml
for 18 h at room temperature, and bound antibody was
detected using the LSAB®2 Peroxidase System (Dako,
Denmark). Staining was then visualized using chromogen
3-amino-9-ethylcarbazole (AEC; 0.4%, Sigma Chemical
Co., St. Louis, MA, USA) for 20 min and counterstained
with Mayer’s haematoxylin. Digital images of the sections
were captured using an Aperio Scanscope (Leica Biosys-
tems, Wetzlar, Germany) and the images were viewed
using the Aperio ImageScope software (Aperio Techno-
logies, Vista, CA, USA). Using these images, microvessel
density (MVD) was determined by manually counting
CD31-positive vessels in five ×0.118 mm2 randomly se-
lected fields at ×200 magnification and results expressed
as mean number of vessels per square millimetres. Then,
intercapillary distance (ICD) was determined using the
Aperio ImageScope ruler tool and by measuring the
distance between a randomly selected index vessel and
the four nearest vessels in each quadrant of a randomly
selected field, with results expressed as the mean of
these distances.
Quantification of microscopic 131I-huA33 tumour uptake
and intratumoural penetration
A detailed analysis was undertaken in patients (3 to 6, 12)
whose tumours contained macroscopic areas of necrosis
by comparing five representative fields in viable peripheral
tumour tissue with five fields in central necrotic tissue.
Mean percent injected dose per cell was determined by
dividing the huA33 uptake (%ID/g), calculated using
the autoradiographic images, by the total number of
cells in each field, determined by manual cell counting in
digitized high-power H&E images. Subsequently, images
of sections stained for CD31-positive blood vessels were
superimposed on their autoradiographic images and five
representative sections from the viable peripheral tissues
were compared with a similar number of sections from
the necrotic central tissue. The mean antibody penetration
Ciprotti et al. EJNMMI Research 2014, 4:22 Page 4 of 10
http://www.ejnmmires.com/content/4/1/22was determined using Aperio ImageScope Ruler Tool and
measuring the distance between five random areas of
huA33 uptake as detected by autoradiography and the
nearest CD31-positive blood vessel as determined by the
superimposed image.Statistical analysis
All statistical analyses were performed with the statistical
software IBM® SPSS® Statistics version 18.0 (SPSS Inc.,
Chicago, IL, USA). All groups were verified for normal
distribution before statistic calculations. All comparisons
across groups were determined using a non-parametric
Mann-Whitney U test. All statistical tests were conducted
using a two-sided alpha level of 0.05.Results
The demographics and tumour characteristics of the 12
patients in this protocol are shown in Table 1. Gamma
camera and SPECT imaging after infusion of 131I-huA33
was sensitive and specific for tumour (representative
images are shown in Figure 1). All lesions in 12 patients
that were detected by imaging were confirmed to be of
primary or metastatic colorectal cancers at surgery.
Patient 7 had a total colectomy yielding three small
primary adenocarcinomas. Tumours from seven patients
(nos 1, 2, 3, 4, 5, 6, and 12) were noted by the pathologist
to have central areas of necrosis, with the tumour from
patient 6 also having stromal elements admixed with
necrotic tissue. A representative image of a tumour with
macroscopic areas of necrosis is shown in Figure 2.
Importantly, all specimens showed that viable tumour
cells expressed GPA33 as determined by immunohis-
tochemistry (IHC) (Figure 3).Table 1 Patient and tumour characteristics according to assig
Patient no. huA33 antibody
dose level (mg/m2)
Sex Age (years)
1 0.25 M 63
2 0.25 F 68
3 0.25 M 56
4 1 M 61
5 1 F 52
6 1 M 66
7 5 M 62
8 5 F 48
9 5 F 60
10 10 F 39
11 10 M 59
12 10 F 49
aTotal volume of tumour identified and measured on CT scan, or at pathology (Pt. 7
P, surgery for primary colon cancer.Table 2 shows 131I-huA33 uptake in tumour measured
by radioactivity gamma well counter and autoradiography.
The mean whole tumour 131I-huA33 uptake measured by
gamma well counter was 5.13 ± 1.76 × 10−3%ID/g, and mean
whole tumour 131I-huA33 uptake measured by autoradi-
ography was virtually identical at 5.12 ± 2.71 × 10−3%ID/g.
Intratumoural uptake of 131I-huA33 was compared in the
periphery and centre of these tumours. There was reduced
uptake in tumour centres compared to tumour periphery
(1.61 ± 1.76 × 10−3%ID/g vs 4.11 ± 2.53 × 10−3%ID/g,
p = 0.07). As a subset of patients exhibited macroscopic
necrosis in their tumours, these results were stratified
by the presence of tumour necrosis (Table 2). This stra-
tification revealed that patients whose tumours were
macroscopically viable in both the centre and the periph-
ery had minimal difference in uptake between regions
(4.12 ± 0.212 × 10−3%ID/g vs 5.39 ± 2.63 × 10−3%ID/g,
p value not available due to limited patient numbers),
whereas patients whose tumours had necrotic centres
showed a trend towards less uptake in the tumour centres
than the tumour periphery, though this was not signi-
ficantly different (0.606 ± 0.493 × 10−3%ID/g vs 2.98 ±
2.17 × 10−3%ID/g, p = 0.06). However, the number of
viable tumour cells was also found to be significantly
lower in central necrotic areas compared to peripheral
viable areas (Table 3; 54 ± 42 vs 313 ± 146, p < 0.001).
Given the significantly different numbers of viable cells
in necrotic versus viable regions, huA33 uptake was
corrected for the differing cell count by calculating the
percent injected dose per cell (%ID/cell). Interestingly,
cellular uptake of huA33 in tumour central necrotic areas
was not significantly different from that in peripheral
viable areas (7.10 ± 5.10 × 10−9 vs 3.82 ± 3.67 × 10−9%ID/
cell respectively, p = 0.4).ned huA33 dose level
Location of tumour
resection or biopsy














). Bx, biopsy at time of intrahepatic artery port insertion; M, metastectomy;
Figure 1 Gamma camera and SPECT imaging after infusion of 131I-huA33. Whole body gamma camera image (a) anterior and (b) posterior
of patient 6 at 6 days following infusion of 131I-huA33. Excellent uptake of 131I-huA33 in extensive liver metastases involving the entire right lobe
of liver (arrow) is evident, with some bowel uptake (double arrows) also seen. Coronal SPECT (c) and transverse SPECT (d) through the right lobe
of liver showing 131I-huA33 uptake in metastatic disease throughout the right lobe of liver, with some central reduced uptake due to necrosis
(confirmed on histology of resected hepatic lobe).
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MVD between these tumours (Table 3). There was a
corresponding reduction in MVD in necrotic versus
viable tumour (19 ± 11 vs 52 ± 20 vessels/mm2, p < 0.001).
Interestingly, we observed that MVD in stromal tissue
was approximately threefold higher than in adjacent
peripheral viable tumour. The mean ICD was also sig-
nificantly wider in the necrotic tumour than areas of
viable tumour, being 207.4 ± 121.7 μm and 69.4 ± 34.5 μm,
respectively (p < 0.001).
Given that that huA33 uptake was preserved despite
the relative hypovascularity of the central necrotic regions,
we examined whether antibody penetration was different
in central necrotic versus peripheral viable tumour regions.
We found that huA33 was able to penetrate further in
necrotic areas rather than viable areas (54.6 ± 23.5 vs
10.5 ± 6.6 μm respectively, p < 0.001). The greatest abso-
lute distance the antibody penetrated was 118 μm in the
centre of necrotic tumours and 26 μm in the periphery.
Discussion
This study clearly demonstrates the ability of an IgG1 anti-
body, huA33, to rapidly penetrate at high concentration
the central necrotic areas of large metastatic colorectal
tumours. At a cellular level, huA33 can target viabletumour clusters at a similar concentration in both necrotic
and viable tumour areas. Importantly, huA33 can traverse
large distances from intratumoural blood vessels, independ-
ent of the interstitial pressure effects present in central
necrotic regions of tumours. These novel observations
highlight the ability of a high affinity and low internalizing
intact antibody to effectively distribute throughout large
tumours and target viable tumour cells at relatively uni-
form and high concentration.
Initial histologic and quantitative autoradiography ana-
lysis of huA33 showed that uptake in necrotic areas
was moderate (0.606 ± 0.493 × 10−3%ID/g), suggesting
that intratumoural interstitial pressure may reduce anti-
body penetration. However, detailed histologic and IHC
analysis demonstrated that necrotic tumour centres had
significantly lower number of viable tumour cells com-
pared to viable peripheral regions and when corrected for
the number of viable tumour cells, uptake of huA33 in
necrotic areas was comparable to that in peripheral viable
tumour areas (7.10 ± 5.10 × 10−9 vs 3.82 ± 3.67 × 10−9%ID/
cell respectively, p = 0.4). Whilst most published studies
have shown reduced antibody uptake in necrotic areas,
Boxer et al. found that, in some cases, patients infused
with antibody to CEA had increased concentrations of
antibody in necrotic more than viable areas of tumour [4].
Figure 2 Representative image of tumour with macroscopic areas of necrosis. Tumour analysis from patient 6. (a) Macroscopic view of ex vivo
liver tissue with extensive tumour infiltration, including viable (blue box) and necrotic (white box) areas. (b) H&E section (magnification ×2) of tissue
from areas of strong 131I-huA33 uptake in macroscopically viable tumour [blue box in (a) and (d)] showing numerous viable tumour clusters with
occasional necrotic/acellular areas. (c) H&E section (magnification ×2) of tissue from area of reduced uptake of 131I-huA33 [white box in (a) and (d)]
showing areas of extensive stroma and necrosis but with some islands of viable tumour. (d) Corresponding ex vivo gamma camera image of tumour
from (a) showing 131I-huA33 uptake in all macroscopic tumour but highest uptake in viable areas (blue box), lesser uptake in necrotic areas (white
box), and no specific uptake in normal liver tissue (upper right edge of specimen). (e, f) Corresponding autoradiographs from (b) and (c), respectively,
showing high uptake in all viable tumour islands, demonstrating that the apparent lack of uptake in macroscopically necrotic tissue is a function of
reduced cell number rather than reduced antibody penetration or cellular uptake.
Figure 3 Representative tumour biopsy (patient 12). (a) Macroscopic view of ex vivo liver tissue with tumour infiltration, including viable (V)
and necrotic (N) areas. (b) Strong and homogenous GPA33 expression in viable tumour, demonstrated by IHC. (c) Autoradiograph of corresponding
tissue in (a) showing high uptake of 131I-huA33 in viable areas and similar degree of uptake by viable cell clusters of tumour within morphologically
necrotic areas of the tumour (arrows). (d) IHC section showing CD-31 positive vessels predominantly in viable areas of tumour.
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Table 2 Percent injected 131I-huA33 dose per gram of tumour measured by gamma well counter and autoradiography
Patient no. Range of tumour uptake %ID/g ×
10−3 (gamma well counter)
Whole tumour %ID/g ×
10−3 (autoradiography)
Tumour centre %ID/g ×
10−3 (autoradiography)
Tumour periphery %ID/g ×
10−3 (autoradiography)
p valued
1 NEa NEa NEa NEa
2 NEa NEa NEa NEa
3 2.7-5.3 NEc 0.556 (N) 0.683
4 5.3-14.1 3.09 0.947 (N) 3.24
5 3.2-7.6 0.837 0.180 (N) 1.02
6 1.7-5.0 NEc 1.25 (N) 4.06
7ab 5.2-6.5 5.77 NEc NEc
7bb NEc 6.22 NEc NEc
7cb 5.2-6.5 6.37 NEc NEc
8 1.4-4.5 NEc 4.27 (V) 3.53
9 3.2-5.5 NEc 3.97 (V) 7.25
10 0.6-5.1 NEc NEc 7.20
11 9.5-12.4 8.43 NEc NEc
12 3.6-8.1 NEc 0.0970 (N) 5.90
Mean ± SD (N) 0.606 ± 0.493 2.98 ± 2.17 0.06
Mean ± SD (V) 4.12 ± 0.212 5.39 ± 2.63 NAe
Mean ± SD (all) 5.13 ± 1.76 5.12 ± 2.71 1.61 ± 1.76 4.11 ± 2.53 0.07
aData from patients 1 and 2 were not available due to technical problems; bpatient 7 had three primary colonic tumours resected and were analyzed separately;
cthe tumours from patients 3, 6, 8, 9, 10, and 12 were too large for whole tumour autoradiographs to be constructed; tumours from patient 7 and 11 were too small to
determine central and peripheral areas; there was no tissue from patient 10 labelled as ‘tumour centre’; dp value comparing 131I-huA33 uptake in tumour centres and
tumour peripheries using Mann-Whitney U test; ep value not available due to limited patient numbers. %ID/g, percent injected dose per gram; N, necrotic areas; V, viable
areas; NE, not evaluable; SD, standard deviation; NA, not applicable.
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we found that tumours without central necrosis dem-
onstrated relatively even antibody distribution following
intravenous administration of the radiolabelled antibody.
Areas of necrosis had lower absolute antibody uptake, but
upon examining uptake per viable tumour cell, the uptake
was similar to homogeneous areas of viable tumour cells.
Interestingly, the ability of huA33 to penetrate into the
necrotic centres of large tumours and localize to viable
tumour cells was not reduced despite the demonstrably
poorer perfusion of these necrotic central areas (long ICD
and low MVD) compared to the periphery (short ICD
and high MVD). Other studies have not found consistent
relationships between degree of vascularity and antibody
uptake in tumours [3-5,8,9,27]. Given the avascular nature
of the necrotic tumour centre, we conclude that huA33
can penetrate long distances from blood vessels before
binding to tumour cells. HuA33 exhibited an average
maximum penetration distance of 82.5 ± 29.3 μm, with
upper limit of this range being 118 μm. This distance
might be even larger if the nearest blood vessels in the
necrotic centre have impaired function and the antibodies
therefore may diffuse in from the vascular capsule of the
tumour. Given that huA33 is a high-affinity antibody [21],
this long penetration distance is an unexpected finding.
This is because very high affinity interactions betweenantibodies and tumour antigens are predicted to impair
efficient tumour penetration of the monoclonal anti-
bodies and thus diminish effective in vivo targeting [28-32].
Similar findings were recently reported by Rudnick et al.
[27], who studied the impact of affinity on the in vivo
tumour-targeting properties of anti-HER2 antibodies.
They found that the highest affinity mAbs exhibited
an average penetration of 20.4 ± 7.5 μm from tumour
blood vessels. Conversely, lowest affinity mAbs revealed
the greatest average penetration distance (84.8 ± 12.8 μm)
and the mAb with a moderate monovalent affinity pen-
etrated to an average distance of 59.7 μm. It is therefore
likely that the low internalization rate of huA33 [33]
contributes to its penetrance capability in tumour, as
internalization plays an important role in antibody capture
and degradation [27].
Other intratumoural factors may contribute to the long
penetration distance of huA33, such as an enhanced
permeability and retention (EPR) effect which is known
to lead to a prolonged retention of drugs into tumour
interstitium [34,35]. Whilst the EPR effect might con-
tribute to the huA33 accumulation and retention in the
necrotic areas of the tumours, preclinical data suggest
that this may be an antibody-specific effect. Ackerman
et al. showed the ability of antibodies against GPA33 to
progress towards a tumour spheroid centre even at very
able 3 Analysis of tumour cell density, vascularity, and antibody penetrance
UMOUR CELL DENSITY
atient no. Mean number of viable tumour cells/field
of viable peripheral tumour areasa
Mean number of viable tumour cells/field







ean±SD 313±146 54±42 P<0.001
ICROVESSEL DENSITY(MVD)
atient no. Mean number of vessels/mm2 in
peripheral tumour areas








ean±SD 52±20 19±11 P<0.001
NTIBODY PENETRATION DISTANCE
atient no. Mean distance cell-vessel (μm) in
peripheral tumour areas (range)
Mean distance cell-vessel (μm) in
central tumour areas (range)
p-valueb
5.5±3 (2.5-10.5) 48.7 ±23.8 (23.8-79.4)
6.7±2.2 (3.9-10) 82.5±29.3 (45.1-118)
14.7±7.8 (3.3-25.2) 53.9±17.4 (33.6-80)
13.7±4.2 (9-18.4) 46.8±8.2 (39.1-59)
2 11.7±9 (1.7-26) 41.1±14.2 (20.3-57.2)
ean±SD 10.5±6.6 54.6±23.5 P<0.001
TERCAPILLARY DISTANCE (ICD)






ean±SD 69.4±34.5 207.4±121.7 P<0.001
ield area = 0.118 mm2.
P-value comparing central versus peripheral tumour areas using Mann-Whitney U Test.



































blow concentrations [33]. They hypothesized that the slow
rate of GPA33 turnover contributes to the ability to pene-
trate spheroids, allowing the bound antibody front to
penetrate without being slowed by binding to replenish
consumed antibody [33]. Aside from antigen turnover
rate, it is also known that for an antibody of any given
affinity, an increase in binding density is associated
with significantly higher monoclonal antibody uptake in
tumour [36-38]. This also appears to be true for huA33,
with O’Donoghue et al. observing a linear relationship
between 124I-huA33 uptake and antigen concentration
in tumour, with estimated binding site occupancy forboth tumour and normal colon of 20% to 50% [22].
Interestingly, O’Donoghue et al. obtained an antibody
uptake of 0.1%ID/mL in focal regions with an average
tumour uptake of 0.017%ID/mL which is among the
highest reported for radiolabeled antibodies, as the
authors concluded. HuA33 uptake observed in our
study was similar to that reported by Welt et al. [39].
It is important to also note that unlike some antibodies
against other tumour antigens [5], huA33 uptake appears
to be universally and strongly present within human
colorectal tumours, a result consistent with previous
studies of murine A33 antibody in vivo [39]. Previous
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of GPA33 in colon cancers and throughout the normal
intestinal mucosa [15,16]. Overall, it seems reasonable to
hypothesize that the favourable GPA33 expression level
and slow internalization rate are major contributors in
determining 131I-huA33 uptake. This is highly relevant to
the design of future studies investigating the therapeutic
potential of huA33, particularly for payload delivery
strategies. One obvious implication of our results is
that patients with large or necrotic tumours should
not be excluded from potential treatment with huA33
because of concerns of poor tumour cell targeting.
Another is that combination therapy with antivascular
agents will also require careful design given their potential
effects on antibody penetration, as also shown in other
studies [40,41] where bevacizumab treatment demon-
strated to impair the penetration of antibodies into the
tumour, resulting in a reduced tumour uptake of these
antibodies.
The limit of our study is the small patient numbers, so
further studies are needed to confirm the present findings.
Conclusions
In summary, targeting GPA33 with huA33 presents a
very attractive option given the universal and uniform
expression of this antigen in colorectal cancers, and,
within the limit of the study, the data presented here
shows excellent uptake in primary and metastatic tumours
of varying size and locations. Tumour cellular uptake is
very high, even in the necrotic centres of tumours where
tumour cell numbers and microvessel densities are very
low, an unusual and therapeutically important finding
for an intact IgG. These findings provide an important
mechanistic support for ongoing clinical trials of huA33
in patients with metastatic colorectal carcinoma and
provide data to rationally design them.
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